BioCentury
ARTICLE | Clinical News

CEGE starts Phase II GVAX AML study

November 27, 2001 8:00 AM UTC

Cell Genesys (CEGE) began a U.S. Phase II trial of GVAX cancer vaccine in combination with bone marrow transplantation in 50 patients with acute myelogenous leukemia (AML). Patients will undergo chemo...